Chimeric aptamers in cancer cell-targeted drug delivery

Kanwar, Jagat R., Roy, Kislay and Kanwar, Rupinder K. 2011, Chimeric aptamers in cancer cell-targeted drug delivery, Critical reviews in biochemistry and molecular biology, vol. 46, no. 6, pp. 459-477.

Attached Files
Name Description MIMEType Size Downloads

Title Chimeric aptamers in cancer cell-targeted drug delivery
Author(s) Kanwar, Jagat R.
Roy, Kislay
Kanwar, Rupinder K.
Journal name Critical reviews in biochemistry and molecular biology
Volume number 46
Issue number 6
Start page 459
End page 477
Total pages 19
Publisher Informa Healthcare
Place of publication London, England
Publication date 2011-12
ISSN 1040-9238
1549-7798
Keyword(s) aptamer
chimera
locked nucleic acid
nanoparticles
SELEX
Si RNA
targeted drug delivery
Summary Aptamers are single-stranded structured oligonucleotides (DNA or RNA) that can bind to a wide range of targets ("apatopes") with high affinity and specificity. These nucleic acid ligands, generated from pools of random-sequence by an in vitro selection process referred to as systematic evolution of ligands by exponential enrichment (SELEX), have now been identified as excellent tools for chemical biology, therapeutic delivery, diagnosis, research, and monitoring therapy in real-time imaging. Today, aptamers represent an interesting class of modern pharmaceuticals which with their low immunogenic potential mimic extend many of the properties of monoclonal antibodies in diagnostics, research, and therapeutics. More recently, chimeric aptamer approach employing many different possible types of chimerization strategies has generated more stable and efficient chimeric aptamers with aptameraptamer, aptamernonaptamer biomacromolecules (siRNAs, proteins) and aptamernanoparticle chimeras. These chimeric aptamers when conjugated with various biomacromolecules like locked nucleic acid (LNA) to potentiate their stability, biodistribution, and targeting efficiency, have facilitated the accurate targeting in preclinical trials. We developed LNA-aptamer (anti-nucleolin and EpCAM) complexes which were loaded in iron-saturated bovine lactofeerin (Fe-blf)-coated dopamine modified surface of superparamagnetic iron oxide (Fe3O4) nanoparticles (SPIONs). This complex was used to deliver the specific aptamers in tumor cells in a co-culture model of normal and cancer cells. This review focuses on the chimeric aptamers, currently in development that are likely to find future practical applications in concert with other therapeutic molecules and modalities.
Language eng
Field of Research 100709 Nanomedicine
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2011, Informa Healthcare
Persistent URL http://hdl.handle.net/10536/DRO/DU:30044317

Document type: Journal Article
Collection: Centre for Biotechnology and Interdisciplinary Sciences (BioDeakin)
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 26 times in TR Web of Science
Scopus Citation Count Cited 31 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 72 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Thu, 05 Apr 2012, 16:06:00 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.